Early Cancer Diagnosis and Genetic Testing Market
完整報告名稱與涵蓋範圍
Early Cancer Diagnosis and Genetic Testing Market Research Report by Product Type (instruments, consumables, and services), by Technology (Chromosomal Genetic Tests, Molecular Testing, Biochemical Testing, and Cellular Testing), by Causative Factors (Infectious agent, Non- Infectious Agent), by Application (Stomach (Gastric) Cancer, Cervical Cancer, Colorectal Cancer, Liver Cancer, Oral Cancer, Lymphoma, and Others), by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035
報告摘要
The Global Early Cancer Diagnosis and Genetic Testing Market is projected to reach USD 26,416.16 million by 2035, growing at a CAGR of 14.41% during 2025–2035. Rising awareness regarding preventive healthcare and increasing adoption of precision medicine are expected to support long-term market growth.
Rising Focus on Early Cancer Detection and Preventive Healthcare
The rising global focus on early cancer detection and preventive healthcare is playing a key role in enlarging the market for early cancer diagnosis and genetic testing on a worldwide scale. Increasing level of understanding, wider screening program implementation, and the development of technologies such as liquid biopsy and genetic testing are not only facilitating earlier diagnosis but also enhancing treatment results and lowering healthcare costs in the long run.
Market Segment Insights
By Product Type
• Instruments – Enable accurate and efficient cancer diagnostics.
• Consumables – Support continuous testing and laboratory workflows.
• Services – Provide specialized diagnostic and genetic analysis support.
By Technology
• Chromosomal Genetic Tests – Detect chromosomal abnormalities linked to cancers.
• Molecular Testing – Identifies gene mutations and cancer biomarkers.
• Biochemical Testing – Measures biological markers for cancer detection.
• Cellular Testing – Examines abnormal cellular changes and behaviors.
By Causative Factors
• Infectious Agent – Infection-related cancers drive diagnostic testing demand.
• Non-Infectious Agent – Lifestyle factors increase cancer screening adoption.
By Application
• Stomach (Gastric) Cancer – Rising cases encourage early gastric cancer screening.
• Cervical Cancer – HPV screening strengthens cervical cancer diagnosis rates.
• Colorectal Cancer – Growing awareness boosts colorectal cancer testing demand.
• Liver Cancer – Hepatitis-linked risks support liver cancer diagnostics.
• Oral Cancer – Tobacco consumption increases oral cancer screening needs.
• Lymphoma – Advanced testing improves lymphoma detection and monitoring.
• Others – Diverse cancer types expand diagnostic application scope.
By End User
• Hospitals & Clinics – Primary centers for cancer diagnosis procedures.
• Diagnostic Laboratories – Handle large-scale genetic and molecular testing.
• Others – Research institutes contribute to diagnostic technology advancements.
North America is leading the worldwide market for early cancer diagnosis and genetic testing due to its advanced oncology facilities, high level of healthcare expenditure, and fast adoption of liquid biopsy techniques, while Europe relies on government initiatives supporting the market and a well-established reimbursement system. On the other hand, the Asia-Pacific region is turning into the most rapidly growing market primarily due to its heavy investments in precision medicine and the increase in cancer awareness, while South America and the Middle East & Africa are showing slow but steady growth as a result of their improving healthcare infrastructures and oncology programs.
Strategic Oncology Expansion
In November 2025, Abbott disclosed its plan to acquire Exact Sciences for USD 21 billion with an aim to reinforce its standing in cancer screening and precision oncology diagnostics. This deal will substantially extend Abbott's portfolio of advanced diagnostics and at the same time, it will bring about a rapid development in cancer detection technologies at an early stage globally.
Expanding Global Partnerships
Strategic partnerships among diagnostic firms, healthcare providers, and technology companies are speeding up innovation in the worldwide market for early cancer diagnosis and genetic testing. With help from these collaborations, companies are expanding their geographical reach, enhancing their commercialization potential, and strengthening their access to leading cancer screening technologies in both developed and developing markets.
Key Report Attributes
• Market Size 2035: USD 26,416.16 Million
• CAGR (2025-2035): 14.41%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Industry Segmentations Growth
• By Product Type: Instruments – 13.66%, Consumables – 14.41%.
• By Technology: Chromosomal Genetic Tests – 13.53%, Molecular Testing – 14.29%.
• By Causative Factors: Infectious agent – 14.97%, Non- Infectious Agent – 13.85%.
• By Application: Stomach (Gastric) Cancer – 16.64%, Cervical Cancer – 14.82%.
• By End User: Hospitals & Clinics – 14.15%, Diagnostic Laboratories – 15.38%.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ......................... 26
2 MARKET INTRODUCTION ...................... 28
2.1 DEFINITION ................................. 28
2.2 SCOPE OF THE STUDY ............. 28
2.3 RESEARCH OBJECTIVE ........... 28
2.4 MARKET STRUCTURE ............. 29
3 RESEARCH METHODOLOGY ................ 30
3.1 OVERVIEW ................................... 30
3.2 DATA FLOW ................................. 32
3.2.1 DATA MINING PROCESS ........................................... 32
3.3 PURCHASED DATABASE: ........ 33
3.4 SECONDARY SOURCES: ........... 34
3.4.1 SECONDARY RESEARCH DATA FLOW: ....................... 35
3.5 PRIMARY RESEARCH: .............. 36
3.5.1 PRIMARY RESEARCH DATA FLOW: ........................... 37
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED .............................. 38
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ............ 38
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ..... 39
3.6.1 REVENUE ANALYSIS APPROACH ............................... 39
3.7 DATA FORECASTING................ 40
3.7.1 DATA FORECASTING TYPE ........................................ 40
3.8 DATA MODELING ....................... 41
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ...................... 41
3.8.2 DATA MODELING: .......... 42
3.9 TEAMS AND ANALYST CONTRIBUTION ..................... 44
4 MARKET DYNAMICS .............................. 46
4.1 INTRODUCTION .......................... 46
4.2 DRIVERS ........................................ 47
4.2.1 RISING GLOBAL CANCER INCIDENCE ......................... 47
4.2.2 GROWING EMPHASIS ON EARLY DETECTION AND PREVENTIVE HEALTHCARE....... 47
4.2.3 INCREASED AWARENESS OF HEREDITARY AND INFECTION-RELATED CANCERS ............................................... 48
4.2.4 EXPANSION OF PRECISION AND PERSONALIZED MEDICINE .................................. 49
4.3 RESTRAINTS ............................... 50
4.3.1 HIGH COST OF ADVANCED DIAGNOSTIC TESTS ......... 50
4.3.2 LIMITED REIMBURSEMENT AND INSURANCE COVERAGE ...................................... 51
4.3.3 REGULATORY AND COMPLIANCE CHALLENGES......... 51
4.4 OPPURTUNITIES ........................ 52
4.4.1 EXPANSION IN EMERGING ECONOMIES ..................... 52
4.4.2 MULTI-CANCER EARLY DETECTION (MCED) AND LIQUID BIOPS ............................. 53
4.4.3 COLLABORATIVE PARTNERSHIPS AND STRATEGIC ALLIANCES ............................ 54
4.4.4 EXPANSION IN BIOCHEMICAL AND CELLULAR TESTING ....................................... 54
5 INDUSTRY TREND ANALYSIS ............... 56
5.1 REGULATORY ENVIRONMENT & COMPLIANCE ....... 56
5.2 TECHNOLOGICAL TRENDS & INNOVATION ................ 58
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..... 62
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ....................................... 66
5.4.1 PRICING ANALYSIS ........ 66
5.4.1.1 NORTH AMERICA ............................................. 66
5.4.1.1.1 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT ................................ 66
5.4.1.2 EUROPE ................ 66
5.4.1.2.1 EUROPE PRICING ANALYSIS, BY PRODUCT.............................................. 66
5.4.1.3 APAC .................... 66
5.4.1.3.1 APAC PRICING ANALYSIS, BY PRODUCT ...... 66
5.4.1.4 REST OF THE WORLD ........................................ 66
5.4.1.4.1 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT .......................... 66
5.4.2 REIMBURSEMENT DYNAMICS ................................... 67
5.5 PESTLE ANALYSIS .................... 67
5.5.1 POLITICAL FACTORS ..... 67
5.5.2 ECONOMIC FACTORS ............................................... 68
5.5.3 SOCIAL FACTORS .......... 68
5.5.4 TECHNOLOGICAL FACTORS ...................................... 69
5.5.5 LEGAL FACTORS ........... 69
5.5.6 ENVIRONMENTAL FACTORS ..................................... 69
5.6 PORTER’S FIVE FORCES MODEL ..................................... 70
5.6.1 THREAT OF NEW ENTRANTS ..................................... 71
5.6.2 BARGAINING POWER OF SUPPLIERS ......................... 72
5.6.3 BARGAINING POWER OF BUYERS .............................. 72
5.6.4 THREAT OF SUBSTITUTES ........................................ 72
5.6.5 INDUSTRY RIVALRY ....... 73
5.7 PRODUCT PIPELINE ANALYSIS ....................................... 73
5.7.1 PRODUCT PIPELINE ANALYSIS .................................. 73
6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE
75
6.1 OVERVIEW ................................... 75
6.2 INSTRUMENTS........................... 76
6.3 CONSUMABLES .......................... 76
6.4 SERVICES ..................................... 77
7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY TECHNOLOGY
78
7.1 OVERVIEW ................................... 78
7.2 CHROMOSOMAL GENETIC TESTS .................................. 80
7.3 MOLECULAR TESTING ............ 80
7.3.1 NEXT-GENERATION SEQUENCING (NGS) ................... 81
7.3.2 POLYMERASE CHAIN REACTION (PCR) ...................... 81
7.3.3 IMMUNOHISTOCHEMISTRY (IHC) .............................. 81
7.3.4 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ........ 82
7.3.5 OTHERS ........................ 82
7.4 BIOCHEMICAL TESTING ......... 82
7.5 CELLULAR TESTING ................. 83
7.5.1 FLOW CYTOMETRY ........ 83
7.5.2 IMMUNOPHENOTYPING ............................................ 83
7.5.3 CELL IMAGING .............. 84
7.5.4 SINGLE-CELL ANALYSIS ............................................ 84
7.5.5 OTHERS ........................ 84
8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY CAUSATIVE
FACTOR ............. 86
8.1 OVERVIEW ................................... 86
8.2 INFECTIOUS AGENT ................. 87
8.2.1 VIRUS ........................... 88
8.2.2 EBV VIRUS .................... 88
8.2.3 HPV VIRUS .................... 89
8.2.4 HEPATITIS VIRUS (HBV) ........................................... 89
8.2.5 MERKEL CELL POLYOMAVIRUS ................................. 90
8.2.6 OTHERS ........................ 90
8.2.7 BACTERIA ..................... 90
8.2.7.1 HELICOBACTER PYLORI .................................... 90
8.2.7.2 SALMONELLA TYPHI ........................................ 91
8.2.7.3 CHLAMYDIA TRACHOMATIS ............................. 91
8.2.7.4 OTHERS ................ 91
8.2.8 FUNGI ........................... 91
8.2.8.1 ASPERGILLUS SPECIES ..................................... 92
8.2.8.2 CANDIDA ALBICANS ......................................... 92
8.2.8.3 OTHERS ................ 93
8.3 NON-INFECTIOUS AGENT ...... 93
9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY APPLICATION 95
9.1 OVERVIEW ................................... 95
9.2 STOMACH (GASTRIC) CANCER ........................................ 96
9.3 CERVICAL CANCER ................... 97
9.4 COLORECTAL CANCER ............ 97
9.5 LIVER CANCER ........................... 97
9.6 ORAL CANCER ............................ 98
9.7 LYMPHOMA ................................ 98
10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET BY END USER ..... 100
10.1 OVERVIEW ................................... 100
10.2 HOSPITALS & CLINICS ............. 101
10.3 DIAGNOSTIC LABORATORIES .......................................... 101
10.4 OTHERS ......................................... 102
11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION ... 103
11.1 OVERVIEW ................................... 103
11.2 NORTH AMERICA ...................... 105
11.2.1 US................................. 112
11.2.2 CANADA ....................... 117
11.3 EUROPE ......................................... 123
11.3.1 GERMANY ..................... 130
11.3.2 FRANCE ........................ 135
11.3.3 UK ................................ 140
11.3.4 SPAIN ........................... 145
11.3.5 ITALY ............................ 150
11.3.6 RUSSIA ......................... 154
11.3.7 REST OF EUROPE ........... 160
11.4 ASIA-PACIFIC .............................. 165
11.4.1 CHINA ........................... 173
11.4.2 INDIA ............................ 178
11.4.3 SOUTH KOREA ............... 189
11.4.4 MALAYSIA .................... 195
11.4.5 THAILAND ..................... 200
11.4.6 INDONESIA .................... 206
11.4.7 REST OF ASIA-PACIFIC ............................................. 211
11.5 SOUTH AMERICA ...................... 217
11.5.1 BRAZIL .......................... 225
11.5.2 MEXICO ........................ 230
11.5.3 ARGENTINA .................. 235
11.5.4 REST OF SOUTH AMERICA ........................................ 241
11.6 MIDDLE EAST AND AFRICA .............................................. 247
11.6.1 GCC COUNTRIES............ 255
11.6.2 SOUTH AFRICA .............. 260
11.6.3 REST OF MEA ................ 266
12 COMPETITIVE LANDSCAPE .................. 273
12.1 INTRODUCTION .......................... 273
12.2 MARKET SHARE ANALYSIS, 2024 ................................. 274
12.3 COMPETITOR DASHBOARD............................................... 275
12.4 PUBLIC PLAYERS STOCK SUMMARY ........................... 276
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ................................... 276
12.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ...... 277
12.1.1 PRODUCT INNOVATION ............................................ 277
12.1.2 ACQUISITION ................ 277
12.1.3 COLLABORATION/PARTNERSHIP .............................. 278
13 COMPANY PROFILES ............................ 279
13.1 ABBOTT ......................................... 279
13.1.1 COMPANY OVERVIEW ............................................... 279
13.1.2 FINANCIAL OVERVIEW .............................................. 280
13.1.3 PRODUCTS/SERVICES OFFERED ................................ 280
13.1.4 KEY DEVELOPMENTS ..... 281
13.1.5 SWOT ANALYSIS ........... 282
13.1.6 KEY STRATEGIES ........... 282
13.2 F. HOFFMANN-LA ROCHE LTD ........................................ 284
13.2.1 COMPANY OVERVIEW ............................................... 284
13.2.2 FINANCIAL OVERVIEW .............................................. 285
13.2.3 PRODUCTS/SERVICES OFFERED ................................ 285
13.2.5 SWOT ANALYSIS ........... 288
13.2.6 KEY STRATEGIES ........... 288
13.3 GE HEALTHCARE ...................... 289
13.3.1 COMPANY OVERVIE ....... 289
13.3.2 FINANCIAL OVERVIEW .............................................. 290
13.3.3 PRODUCTS OFFERED ..... 290
13.3.5 SWOT ANALYSIS ........... 291
13.3.6 KEY STRATEGIES ........... 292
13.4.5 SWOT ANALYSIS ........... 296
13.5 BD ......... 298
13.5.1 COMPANY OVERVIEW ............................................... 298
13.5.2 FINANCIAL OVERVIEW .............................................. 299
13.5.3 PRODUCTS OFFERED ..... 299
13.5.5 SWOT ANALYSIS ........... 300
13.5.6 KEY STRATEGY .............. 300
13.6 SIEMENS HEALTHINEERS AG ......................................... 302
13.6.1 COMPANY OVERVIEW ............................................... 302
13.6.2 FINANCIAL OVERVIEW .............................................. 303
13.6.3 PRODUCTS/SERVICES OFFERED ................................ 303
13.6.5 SWOT ANALYSIS ........... 304
13.6.6 KEY STRATEGIES ........... 304
13.7 HOLOGIC, INC. .............................. 306
13.7.1 COMPANY OVERVIEW ............................................... 306
13.7.2 FINANCIAL OVERVIEW .............................................. 307
13.7.3 PRODUCTS OFFERED ..... 307
13.7.5 SWOT ANALYSIS ........... 308
13.7.6 KEY STRATEGIES ........... 308
13.8.5 SWOT ANALYSIS ........... 312
13.9 ILLUMINA, INC. .......................... 314
13.9.1 COMPANY OVERVIEW ............................................... 314
13.9.2 FINANCIAL OVERVIEW .............................................. 315
13.9.3 PRODUCTS OFFERED ..... 315
13.9.5 SWOT ANALYSIS ........... 316
13.9.6 KEY STRATEGY .............. 316
13.10 QUEST DIAGNOSTICS ............... 318
13.10.1 COMPANY OVERVIEW ............................................... 318
13.10.2 FINANCIAL OVERVIEW .............................................. 319
13.10.3 PRODUCTS/SERVICES OFFERED ................................ 319
13.10.4 KEY DEVELOPMENTS ..... 320
13.10.5 SWOT ANALYSIS ........... 321
13.10.6 KEY STRATEGIES ........... 321
14 DATA CITATIONS ................................... 322
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 43
TABLE 2 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 76
TABLE 3 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 79
TABLE 4 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD
MILLION) 80
TABLE 5 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
83
TABLE 6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 87
TABLE 7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR INFECTIOUS AGENT, BY TYPE, 2019–2035 (USD MILLION)
87
TABLE 8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) 88
TABLE 9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION) 90
TABLE 10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) 92
TABLE 11 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 96
TABLE 12 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY END USER, 2019–2035 (USD MILLION) 101
TABLE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY REGION, 2019-2035 103
TABLE 2 NORTH AMERICA EARLY CANCER DIAGNOSIS TESTING MARKET, BY COUNTRY, 2019-2035 106
TABLE 3 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 107
TABLE 4 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 107
TABLE 5 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION)
108
TABLE 6 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION)
108
TABLE 7 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 109
TABLE 8 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD
MILLION) 109
TABLE 9 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 110
TABLE 10 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 110
TABLE 11 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 111
TABLE 12 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111
TABLE 13 NORTH AMERICA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 112
TABLE 14 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 112
TABLE 15 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 113
TABLE 16 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 113
TABLE 17 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 114
TABLE 18 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 114
TABLE 19 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 114
TABLE 20 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 115
TABLE 21 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 115
TABLE 22 US: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 116
TABLE 23 US: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 116
TABLE 24 US: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 117
TABLE 25 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 117
TABLE 26 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 118
TABLE 27 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 118
TABLE 28 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 119
TABLE 29 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 119
TABLE 30 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
120
TABLE 31 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 120
TABLE 32 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 121
TABLE 33 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 121
TABLE 34 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 122
TABLE 35 CANADA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 122
TABLE 36 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 124
TABLE 37 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 125
TABLE 38 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 125
TABLE 39 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 126
TABLE 40 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 126
TABLE 41 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 127
TABLE 42 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
127
TABLE 43 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 128
TABLE 44 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 128
TABLE 45 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 129
TABLE 46 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 129
TABLE 47 EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 130
TABLE 48 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 130
TABLE 49 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 131
TABLE 50 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 131
TABLE 51 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 132
TABLE 52 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
132
TABLE 53 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 133
TABLE 54 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 133
TABLE 55 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 134
TABLE 56 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 134
TABLE 57 GERMANY: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 135
TABLE 58 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 135
TABLE 59 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 136
TABLE 60 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 136
TABLE 61 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 137
TABLE 62 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 137
TABLE 63 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
137
TABLE 64 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 138
TABLE 65 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 138
TABLE 66 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 139
TABLE 67 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 139
TABLE 68 FRANCE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 140
TABLE 69 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 140
TABLE 70 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 141
TABLE 71 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 141
TABLE 72 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 142
TABLE 73 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION) 142
TABLE 74 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 142
TABLE 75 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 143
TABLE 76 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 143
TABLE 77 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 144
TABLE 78 UK: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 144
TABLE 79 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 145
TABLE 80 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 145
TABLE 81 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 146
TABLE 82 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 146
TABLE 83 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 147
TABLE 84 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
147
TABLE 85 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 147
TABLE 86 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 148
TABLE 87 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 148
TABLE 88 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 149
TABLE 89 SPAIN: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 149
TABLE 90 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 150
TABLE 91 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 150
TABLE 92 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 151
TABLE 93 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 151
TABLE 94 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 152
TABLE 95 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
152
TABLE 96 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 152
TABLE 97 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 153
TABLE 98 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION) 153
TABLE 99 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 153
TABLE 100 ITALY: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION) 154
TABLE 101 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 154
TABLE 102 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION) 155
TABLE 103 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 155
TABLE 104 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION) 156
TABLE 105 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION) 156
TABLE 106 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
157
TABLE 107 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION) 157
TABLE 108 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION) 158
TABLE 109 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION)
TABLE 110 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 111 RUSSIA: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION)
TABLE 112 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 113 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 114 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR MOLECULAR TESTING I BY TYPE, 2019–2035 (USD MILLION)
161
TABLE 115 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR CELLULAR TESTING I BY TYPE, 2019–2035 (USD MILLION)
161
TABLE 116 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
162
TABLE 117 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR INFECTIOUS AGENT I BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
162
TABLE 118 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR VIRUS I BY TYPE, 2019–2035 (USD MILLION)
TABLE 119 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR BACTERIA I BY TYPE, 2019–2035 (USD MILLION)
TABLE 120 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, FOR FUNGI I BY TYPE, 2019–2035 (USD MILLION)
TABLE 121 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 122 REST OF EUROPE: EARLY CANCER DIAGNOSIS TESTING MARKET, END USER, 2019–2035 (USD MILLION)
TABLE 123 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 124 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 125 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 126 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
168
TABLE 127 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
169
TABLE 128 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
169
TABLE 129 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 130 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 131 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 132 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 133 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 134 ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 135 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 136 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 137 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 174
TABLE 138 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
TABLE 139 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
TABLE 140 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 141 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 142 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 143 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 144 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 145 CHINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 146 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 147 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 148 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 179
TABLE 149 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
180
TABLE 150 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
180
TABLE 151 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD MILLION)
181
TABLE 152 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 153 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 154 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 155 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 156 INDIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 157 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 158 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 159 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 185
TABLE 160 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
185
TABLE 161 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
TABLE 162 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 163 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 164 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 165 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 166 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 167 JAPAN: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 168 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 169 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 170 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
190
TABLE 171 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
191
TABLE 172 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
191
TABLE 173 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
192
TABLE 174 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 175 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 176 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 177 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 178 SOUTH KOREA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 179 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 180 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 181 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
196
TABLE 182 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 196
TABLE 183 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
197
TABLE 184 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
197
TABLE 185 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 186 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 187 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 188 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 189 MALAYSIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 190 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 191 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
199
TABLE 192 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
201
TABLE 193 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 202
TABLE 194 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
202
TABLE 195 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
203
TABLE 196 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 197 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 198 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 199 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 200 THAILAND: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 201 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 202 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 203 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
207
TABLE 204 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 207
TABLE 205 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
208
TABLE 206 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
208
TABLE 207 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 208 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 209 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 210 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 211 INDONESIA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 212 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 213 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 214 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD
MILLION)
212
TABLE 215 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD
MILLION)
213
TABLE 216 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
213
TABLE 217 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019
2035 (USD MILLION)
214
TABLE 218 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION) 214
TABLE 219 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
215
TABLE 220 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION) 215
TABLE 221 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
216
TABLE 222 REST OF ASIA-PACIFIC: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 223 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 224 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 225 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 226 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD
MILLION)
220
220
TABLE 227 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
221
TABLE 228 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
221
TABLE 229 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035
(USD MILLION)
222
TABLE 230 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 231 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 232 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 233 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 234 SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 235 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 236 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
225
TABLE 237 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 226
TABLE 238 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
226
TABLE 239 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
TABLE 240 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 241 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 242 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 243 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 244 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 245 BRAZIL: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 246 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 247 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 248 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 231
TABLE 249 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION) 231
TABLE 250 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
232
TABLE 251 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 252 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 253 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 254 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 255 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 256 MEXICO: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 257 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION)
TABLE 258 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION)
TABLE 259 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
236
TABLE 260 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD MILLION)
237
TABLE 261 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
237
TABLE 262 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE, 2019–2035 (USD
MILLION)
TABLE 263 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
TABLE 264 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
TABLE 265 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
TABLE 266 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION)
TABLE 267 ARGENTINA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
TABLE 268 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 241
TABLE 269 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY TECHNOLOGY, 2019–2035 (USD MILLION) 241
TABLE 270 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR MOLECULAR TESTING, BY TYPE, 2019–2035
(USD MILLION)
242
TABLE 271 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR CELLULAR TESTING, BY TYPE, 2019–2035 (USD
MILLION)
242
TABLE 272 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY CAUSATIVE FACTOR, 2019–2035 (USD MILLION)
243
TABLE 273 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR INFECTIOUS AGENT, BY PATHOGEN TYPE,
2019–2035 (USD MILLION)
243
TABLE 274 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR VIRUS, BY TYPE, 2019–2035 (USD MILLION)
244
TABLE 275 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR BACTERIA, BY TYPE, 2019–2035 (USD MILLION)
244
TABLE 276 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, FOR FUNGI, BY TYPE, 2019–2035 (USD MILLION)
245
TABLE 277 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY APPLICATION, 2019–2035 (USD MILLION) 245
TABLE 278 REST OF SOUTH AMERICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY END USER, 2019–2035 (USD MILLION)
246
TABLE 279 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
248
TABLE 280 MIDDLE EAST AND AFRICA: EARLY CANCER DIAGNOSIS AND GENETIC TESTING, BY PRODUCT TYPE, 2019–2035 (USD MILLION) 249
TABL
LIST OF FIGURES
FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET: STRUCTURE 29
FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET: GROWTH FACTOR ANALYSIS (2019-2035) 46
FIGURE 2 DRIVER IMPACT ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 50
FIGURE 3 RESTRAINT IMPACT ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 52
FIGURE 4 PORTER FIVE FORCE ANALYSIS: GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET 71
FIGURE 5 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, PRODUCT TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035
(USD MILLION) 75
FIGURE 6 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY PRODUCT TYPE, 2024 & 2035 (USD MILLION) 75
FIGURE 7 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY PRODUCT TYPE, 2024 77
FIGURE 8 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD
MILLION) 78
FIGURE 9 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY TECHNOLOGY, 2024 & 2035 (USD MILLION) 79
FIGURE 10 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY TECHNOLOGY, 2024 85
FIGURE 11 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, CAUSATIVE FACTOR SEGMENT ATTRACTIVENESS, 2024 &
2035 (USD MILLION) 86
FIGURE 12 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY CAUSATIVE FACTOR, 2024 & 2035 (USD MILLION) 86
FIGURE 13 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), CAUSATIVE FACTOR, 2024 93
FIGURE 14 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD
MILLION) 95
FIGURE 15 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 96
FIGURE 16 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), APPLICATION, 2024 99
FIGURE 17 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD
MILLION) 100
FIGURE 18 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY END USER, 2024 & 2035 (USD MILLION) 100
FIGURE 19 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), END USER, 2024 102
FIGURE 20 GLOBAL MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 103
FIGURE 1 GLOBAL EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY REGION, 2024 (% SHARE) 104
FIGURE 2 NORTH AMERICA MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 105
FIGURE 3 NORTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 106
FIGURE 4 NORTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 106
FIGURE 5 EUROPE MARKET ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, 2019-2035 (USD MILLION) 123
FIGURE 6 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 124
FIGURE 7 EUROPE EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 125
FIGURE 8 ASIA-PACIFIC MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 165
FIGURE 9 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 165
FIGURE 10 ASIA-PACIFIC EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 167
FIGURE 11 SOUTH AMERICA MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 217
FIGURE 12 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 218
FIGURE 13 SOUTH AMERICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 219
FIGURE 14 MIDDLE EAST AND AFRICA MARKET SWOT ANALYSIS: EARLY CANCER DIAGNOSIS AND GENETIC TESTING 247
FIGURE 15 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
248
FIGURE 16 MIDDLE EAST AND AFRICA EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET SHARE (%), BY COUNTRY, 2024 249
FIGURE 17 EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
FIGURE 18 COMPETITOR DASHBOARD: EARLY CANCER DIAGNOSIS AND GENETIC TESTING MARKET
FIGURE 19 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 ABBOTT: SWOT ANALYSIS
FIGURE 21 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 23 GE HEALTHCARE: SWOT ANALYSIS
FIGURE 25 QIAGEN: SWOT ANALYSIS
FIGURE 26 BD: SWOT ANALYSIS
FIGURE 27 SIEMENS HEALTHINEERS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 SIEMENS HEALTHINEERS AG: SWOT ANALYSIS
FIGURE 29 HOLOGIC, INC.: SWOT ANALYSIS
FIGURE 31 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 32 ILLUMINA, INC.: SWOT ANALYSIS
FIGURE 33 QUEST DIAGNOSTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 QUEST DIAGNOSTICS: SWOT ANALYSIS
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們